Food Allergy Treatment Market to Grow with a CAGR of 8.20% through 2029

Rising Prevalence of Food Allergies and Improved Diagnostic Technologies are expected to drive the Global Food Allergy Treatment Market growth in the forecast period, 2025-2029

According to TechSci Research report, “Food Allergy Treatment Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029”, the Global Food Allergy Treatment Market stood at USD 6.85 Billion in 2023 and is anticipated to grow with a CAGR of 8.20% in the forecast period, 2025-2029.

The global food allergy treatment market is experiencing a transformative phase, largely driven by the introduction of cutting-edge therapies such as oral immunotherapy (OIT), epinephrine auto-injectors, and biologics like monoclonal antibodies. These advancements are designed to tackle the core mechanisms of allergic reactions, such as IgE-mediated immune responses, by progressively desensitizing the immune system to allergens. The growing variety of treatment options is catalyzing the expansion of the market, as patients seek more effective solutions that go beyond symptom management and focus on long-term desensitization.

One of the key factors accelerating demand for these treatments is food adulteration, which has resulted in unintended exposure to allergens in common food products. As consumers and healthcare professionals become increasingly aware of the risks associated with hidden allergens, the need for reliable allergy management solutions has grown significantly. This heightened awareness has led to an increase in demand not only for allergy treatments but also for safe, allergen-free food alternatives, which in turn is driving innovation and regulatory action in food labeling and safety standards. Substantial investments in research and development (R&D) by leading pharmaceutical companies, coupled with governmental and healthcare institutional funding, are fueling innovation in the allergy treatment space. These financial commitments have enabled the development of novel therapies and diagnostic tools, creating a favorable environment for further market growth. Pharmaceutical companies are actively exploring ways to improve treatment efficacy, shorten treatment timelines, and enhance patient adherence, particularly as the prevalence of food allergies rises globally.

Regulatory advancements, particularly the FDA's approval of Xolair for treating IgE-mediated food allergies, have been pivotal in advancing the market for biologic treatments. As more regulatory bodies approve innovative therapies, such as biologics and immunotherapies, the acceptance and availability of these treatments have expanded across global markets. This regulatory momentum has not only accelerated market growth but also established a clearer pathway for future treatments to gain approval. Challenges remain, such as treatment accessibility in low-income regions, where high treatment costs and limited healthcare infrastructure continue to pose significant barriers. Additionally, the rise of biosimilars—less expensive alternatives to biologics—may create pricing pressures and shift market dynamics, requiring companies to adjust pricing strategies and focus on differentiating their products through efficacy, safety, and patient experience.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Food Allergy Treatment Market”

The Global Food Allergy Treatment Market is segmented into allergen type, drug type, route of administration, end user, regional distribution, and company.

Based on its Route of Administration, the Parenteral Route segment has emerged as the predominant market leader, Food allergies, especially severe ones, can lead to anaphylaxis, a life-threatening reaction that requires rapid intervention. Parenteral treatments, particularly epinephrine administered through auto-injectors (such as the EpiPen), are the first-line therapy for anaphylaxis due to their ability to act quickly and effectively. This fast-acting response is crucial in stabilizing the patient and preventing further complications, such as airway constriction or shock, following accidental food exposure. The subcutaneous administration of epinephrine via auto-injectors has become the standard of care in both home and clinical settings, contributing to the widespread adoption and dominance of the parenteral route in food allergy management​

The parenteral route’s dominance is reinforced by strong regulatory support. The FDA approval of epinephrine auto-injectors, along with emerging biologics and monoclonal antibodies for food allergies, has established parenteral administration as a key method for managing food allergies. Regulatory agencies have acknowledged the need for efficient, fast-acting treatments to reduce the risks associated with food-induced anaphylaxis, resulting in an expanding array of parenteral products being approved for food allergy treatment​. This has created a strong market presence for injectable therapies compared to other routes like oral administration. Beyond emergency interventions, parenteral treatments like biologics (e.g., omalizumab, marketed as Xolair) are increasingly used for the long-term management of food allergies. These biologics, which are administered via subcutaneous injections, target the underlying immune mechanisms responsible for allergic reactions, particularly IgE-mediated food allergies. By reducing IgE levels, biologics can help prevent allergic responses over time, providing a more durable solution compared to other routes, such as oral therapies. These long-term management options further boost the dominance of parenteral treatments in the market.

The Asia Pacific region is poised to experience the fastest growth in the Global food allergy treatment market. food allergies have been less common in APAC compared to regions like North America and Europe. However, this trend is rapidly changing. Studies have shown a significant rise in the prevalence of food allergies, particularly among children, in countries like China, Japan, and India. Factors such as changing diets, urbanization, and environmental changes are contributing to this surge​. As more people are diagnosed with food allergies, the demand for effective treatments and management options is increasing, driving market growth in the region. In many parts of Asia Pacific, awareness of food allergies is growing, particularly in urban areas, thanks to increasing health education, media coverage, and advocacy. Public health campaigns and improved education about the dangers of food allergies are helping to drive early diagnosis and treatment. This awareness is also leading to an increasing demand for treatment options, including oral immunotherapy (OIT) and epinephrine auto-injectors​.

Healthcare infrastructure in key APAC markets is also evolving. Countries such as China, India, and South Korea have seen significant investments in healthcare systems and services, which are improving access to both allergy specialists and treatments. This is enabling more people to seek diagnosis and care for food allergies, further boosting the market.

As the incidence of food allergies increases in the region, regulatory bodies in APAC countries are beginning to focus more on the approval of novel allergy treatments. For example, China and India have been adopting more rigorous regulatory frameworks for new drug approvals, and as more allergy treatments, including monoclonal antibodies and biologics, gain approval in these markets, they are expected to be rapidly adopted​. Japan has long been at the forefront of adopting cutting-edge treatments, and with regulatory advancements, the availability of approved allergy therapies is growing. These regulatory developments are critical for fostering market growth by ensuring that innovative treatments reach a wider patient base across the region.

Major companies operating in Global Food Allergy Treatment Market are:

• Sanofi
• STALLERGENES GREER International AG
• DBV Technologies
• Vedanta Biosciences, Inc.
• Alladapt Immunotherapeutics, Inc.
• COUR Pharmaceuticals Development Company, Inc
• Aravax
• Prota Therapeutics Pty Ltd
• Teva Pharmaceutical Industries Ltd.
• F. Hoffmann-La Roche Ltd

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The global food allergy treatment market is on an accelerated growth trajectory, driven by increasing prevalence rates, the expansion of innovative therapies, and heightened awareness surrounding food allergens. The advent of cutting-edge treatments such as oral immunotherapy (OIT), epinephrine auto-injectors, and biologics like monoclonal antibodies are revolutionizing how food allergies are managed, offering both emergency relief and long-term solutions. Regulatory advancements, particularly with the approval of novel therapies by agencies like the FDA, further fuel the market’s expansion, while regions such as Asia Pacific are emerging as key contributors to future growth, supported by economic development, increased healthcare access, and rising awareness.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Food Allergy Treatment Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Allergen Type (Dairy Products, Poultry Product, Tree Nuts, Peanuts, Shellfish, Wheat, Soys, Other), By Drug Type (Antihistamines, Epinephrine, Immunotherapy), By Route of Administration (Oral, Parenteral, Other), By End User (Hospital Pharmacies, Retail Pharmacies, Others), By Region, & Competition, 2019-2029F”, has evaluated the future growth potential of Global Food Allergy Treatment Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Food Allergy Treatment Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]